CliffBio
small molecule

ARIXTRA

FONDAPARINUX SODIUM

Loss of exclusivity—loss of exclusivity
CompanyMYLAN IRELAND LTD

Drug detail

Brand nameARIXTRA
Active ingredientFONDAPARINUX SODIUM
Strength7.5MG/0.6ML (7.5MG/0.6ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalMay 2004
Marketing statusRX

More from MYLAN IRELAND LTD

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ARIXTRA patent cliff — loss of exclusivity — | CliffBio